eScholarship
metadata only
CC BY-NC-ND
High integrin α3 expression is associated with poor prognosis in patients with non-small cell lung cancer
BACKGROUND: We previously showed that α3β1 integrin is a novel cancer biomarker and drug target in non-small cell lung cancer (NSCLC). This study characterized the integrin α3 (ITGA3) expression on patient specimens. METHODS: Tissue microarrays (TMAs) were prepared from archival tissue blocks contai
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Identification of Integrin ab Expression in Lung Cancer Patients#859376
- Loss of EMILIN-1/integrin axis drives microenvironmental reprogramming in gastric tumorigenesis.#615832
- AI-driven multi-omics biomarkers in precision breast cancer therapeutics: from discovery to clinical translation.#1346466
- IMaging Pilot Study of the αvβ6 Integrin Radiotracer [18F]-A20FMDV2 in PAtients With Solid Cancer Types#832031
- Integrin αVβ3 as a context‑dependent regulator of bone homeostasis: Insights into osteoporosis pathogenesis and therapeutic targeting (Review).#1097949
Record · ID 1341219
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive